Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 5
2004 6
2005 2
2006 3
2007 5
2008 3
2009 3
2010 2
2011 8
2012 5
2013 7
2014 9
2015 6
2016 13
2017 14
2018 12
2019 19
2020 19
2021 23
2022 29
2023 23
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation.
Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, Wang J, Hollingsworth LR, Magupalli VG, Zhao L, Luo HR, Kim J, Lieberman J, Wu H. Hu JJ, et al. Among authors: luo x. Nat Immunol. 2020 Jul;21(7):736-745. doi: 10.1038/s41590-020-0669-6. Epub 2020 May 4. Nat Immunol. 2020. PMID: 32367036 Free PMC article.
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: luo x. Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. Nat Commun. 2024. PMID: 38480701 Free PMC article.
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: luo x. Res Sq [Preprint]. 2023 Jul 10:rs.3.rs-2966905. doi: 10.21203/rs.3.rs-2966905/v1. Res Sq. 2023. PMID: 37502925 Free PMC article. Updated. Preprint.
Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity.
Johnson BA, Hage A, Kalveram B, Mears M, Plante JA, Rodriguez SE, Ding Z, Luo X, Bente D, Bradrick SS, Freiberg AN, Popov V, Rajsbaum R, Rossi S, Russell WK, Menachery VD. Johnson BA, et al. Among authors: luo x. J Virol. 2019 Oct 29;93(22):e01282-19. doi: 10.1128/JVI.01282-19. Print 2019 Nov 15. J Virol. 2019. PMID: 31462558 Free PMC article.
1,3,5-Tris(4-meth-oxy-phen-yl)-1,3,5-triazinane-2,4,6-trione.
Fang L, Li F, Luo X. Fang L, et al. Among authors: luo x. Acta Crystallogr Sect E Struct Rep Online. 2014 Jan 8;70(Pt 2):o118. doi: 10.1107/S160053681303482X. eCollection 2014 Feb 1. Acta Crystallogr Sect E Struct Rep Online. 2014. PMID: 24764847 Free PMC article.
200 results